Doxazosin Mesylate

Catalog No.S1324

Doxazosin Mesylate Chemical Structure

Molecular Weight(MW): 547.58

Doxazosin, a quinazoline-derivative, selectively antagonizes postsynaptic α1-adrenergic receptors, used in the treatment of high blood pressure and urinary retention associated with benign prostatic hyperplasia.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 4 Publications

3 Customer Reviews

  • J Clin Invest 2013 123(12), 5119-34. Doxazosin Mesylate purchased from Selleck.

    Cytotoxicity, caspase-3 activity and autophagy induced by treatment of PC-3 and LNCap cells with prazosin or doxazosin for 24 hr. The presence of autophagosomes was visualized by fluorescent microscopy.

    Prostate, 2016, 76(8):757-66. Doxazosin Mesylate purchased from Selleck.

  • Effects of doxazosin on CNV lesion thickness 7 and 14 days after laser induction. Light micrographs of H&E-stained sections of CNV lesions in the control group after 7 days (A), in the doxazosin-treated group after 7 days (B), in the control group after 14 days (D), and in the doxazosin-treated group after 14 days (E) are shown. CNV thickness in the doxazosin-treated group was significantly lower compared to the control group (C, F: ***P < 0.001). The distance between the two white arrows indicates CNV thickness. Scale bar, 100 mm. H&E, hematoxylin and eosin.

    J Ocul Pharmacol Ther, 2017, 33(1):50-56. Doxazosin Mesylate purchased from Selleck.

Purity & Quality Control

Choose Selective Adrenergic Receptor Inhibitors

Biological Activity

Description Doxazosin, a quinazoline-derivative, selectively antagonizes postsynaptic α1-adrenergic receptors, used in the treatment of high blood pressure and urinary retention associated with benign prostatic hyperplasia.
Targets
α1-adrenergic receptor [1]
In vitro

Doxazosin-induced apoptosis is blocked by specific caspase-8 inhibitors, supporting the functional involvement of caspase-8 in doxazosin-induced apoptosis. Doxazosin increases FADD recruitment and subsequent caspase-8 activation, implicating Fas-mediated apoptosis as the underlying mechanism of the effect of Doxazosin in prostate cells. [1] Doxazosin and cholestyramine similarly decreases plasma total and LDL plus VLDL cholesterols, and total triglycerides on average by 46%, 61% and 45% respectively. [2] Doxazosin induces DNA damage and cell death in HL-1 cell line. Doxazosin treatment decreases cell viability in primary cultures of neonatal rat cardiomyocytes, and Hoechst dye vital staining demonstrates doxazosin-induced apoptosis in primary cultures of human adult cardiomyocytes. [3] Doxazosin antagonizes the VEGF-mediated angiogenic response of HUVEC cells, by abrogating cell adhesion to fibronectin and collagen-coated surfaces and inhibiting cell migration, via a potential downregulation of VEGF expression. [4]

In vivo Doxazosin also reduces mean arterial pressure by 18% without affecting heart rate in all hamsters. [2] Doxazosin causes a significant reduction in the wet weight of BabeTGF-beta 1-infected mouse prostate reconstitution (MPR). [5]

Protocol

Solubility (25°C)

In vitro DMSO 15 mg/mL (27.39 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 547.58
Formula

C23H25N5O5.CH4O3S

CAS No. 77883-43-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03339258 Recruiting Stress Disorders Post-Traumatic San Francisco Veterans Affairs Medical Center|United States Department of Defense|Northern California Institute of Research and Education April 15 2018 Phase 2
NCT03339258 Recruiting Stress Disorders Post-Traumatic San Francisco Veterans Affairs Medical Center|United States Department of Defense|Northern California Institute of Research and Education April 15 2018 Phase 2
NCT01003886 Completed Prostatic Hyperplasia Pfizer May 2009 --
NCT01003886 Completed Prostatic Hyperplasia Pfizer May 2009 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Adrenergic Receptor Signaling Pathway Map

Related Adrenergic Receptor Products0

Tags: buy Doxazosin Mesylate | Doxazosin Mesylate ic50 | Doxazosin Mesylate price | Doxazosin Mesylate cost | Doxazosin Mesylate solubility dmso | Doxazosin Mesylate purchase | Doxazosin Mesylate manufacturer | Doxazosin Mesylate research buy | Doxazosin Mesylate order | Doxazosin Mesylate mouse | Doxazosin Mesylate chemical structure | Doxazosin Mesylate mw | Doxazosin Mesylate molecular weight | Doxazosin Mesylate datasheet | Doxazosin Mesylate supplier | Doxazosin Mesylate in vitro | Doxazosin Mesylate cell line | Doxazosin Mesylate concentration | Doxazosin Mesylate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID